Stay Current at INTERPHEX - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Stay Current at INTERPHEX
An established show has several new programs that reflect the industry's current challenges.


Pharmaceutical Technology
Volume 34, Issue 4, pp. 14


Erik Greb
In addition to showcasing the latest innovations in pharmaceutical manufacturing equipment, INTERPHEX 2010 will help attendees stay current through various new presentations and discussions. Pharmaceutical Technology is partnering with INTERPHEX to present speakers from the US Food and Drug Administration, Rx–360, and PharmSource, a provider of business intelligence. Conference visitors will hear representatives of these groups discuss deficiencies in new drug applications, trends in supply-chain security, and the state of the outsourcing industry. Best of all, the speakers will take time to answer questions from the audience.

Although INTERPHEX is associated with small-molecule manufacturing, the conference is broadening its offerings for professionals involved in large-molecule production. BioPharm International, our sister publication, organized the keynote presentation this year about the effect of healthcare reform on the biopharmaceutical industry. MSNBC's Chris Matthews will moderate the discussion.

And each day, my colleagues and I will be conducting live interviews with various industry experts. We'll be giving you the scoop about quality-by-design implementation, packaging innovations, harmonization, and high-potency drugs. Our interviews will be videotaped and featured on our website after the conference.

INTERPHEX 2010 promises to keep attendees informed about the latest trends and innovations shaping the drug industry. I hope to see you there!

Check out PharmTech's preliminary program for its live video interviews at Interphex 2010

Erik Greb is an assistant editor of Pharmaceutical Technology.

Read Erik's blogs at http://blog.PharmTech.com/.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here